881 related articles for article (PubMed ID: 30695864)
1. [Clinicopathological characteristics of fumarate hydratase-deficient renal cell carcinoma].
Zhang W; Chu J; Zou YW; Jiang YX; Wei ZM; Zhong DC; Liu Y; Li YJ; Yu WJ
Zhonghua Bing Li Xue Za Zhi; 2019 Feb; 48(2):120-126. PubMed ID: 30695864
[No Abstract] [Full Text] [Related]
2. [Clinicopathological features and prognosis of fumarate hydratase deficient renal cell carcinoma].
Yu YF; He SM; Wu YC; Xiong SW; Shen Q; Li YY; Yang F; He Q; Li XS
Beijing Da Xue Xue Bao Yi Xue Ban; 2021 Aug; 53(4):640-646. PubMed ID: 34393221
[TBL] [Abstract][Full Text] [Related]
3. [Clinicopatholigic features of renal cell carcinoma associated with chromosome X inversion harboring gene fusions involving TFE3].
Zhao YN; Wang XT; Xia QY; Wang GP; Sun SY; Zhao LF; Zhou XJ; Rao Q
Zhonghua Bing Li Xue Za Zhi; 2018 Aug; 47(8):574-579. PubMed ID: 30107660
[No Abstract] [Full Text] [Related]
4. [Acquired cystic kidney disease-associated renal cell carcinoma: a clinicopathologic study of three cases].
Zhang W; Xu LL; Yu WJ; Wang Q; Jiang YX; Liu Y; Li YJ
Zhonghua Bing Li Xue Za Zhi; 2018 May; 47(5):366-371. PubMed ID: 29783804
[No Abstract] [Full Text] [Related]
5. Fumarate hydratase-deficient renal cell carcinoma: A clinicopathological study of seven cases including hereditary and sporadic forms.
Kuroda N; Tsutsui M; Iguchi M; Nobuoka E; Uehara T; Sonobe Y; Morinaga Y; Shibuya S; Oda W; Yanai H; Kawada C; Karashima T; Yamasaki I; Inoue K; Nagashima Y
Ann Diagn Pathol; 2020 Dec; 49():151599. PubMed ID: 32977234
[TBL] [Abstract][Full Text] [Related]
6. A Clinicopathologic and Molecular Analysis of Fumarate Hydratase-deficient Renal Cell Carcinoma in 32 Patients.
Lau HD; Chan E; Fan AC; Kunder CA; Williamson SR; Zhou M; Idrees MT; Maclean FM; Gill AJ; Kao CS
Am J Surg Pathol; 2020 Jan; 44(1):98-110. PubMed ID: 31524643
[TBL] [Abstract][Full Text] [Related]
7. Fumaratehydratase-deficient renal cell carcinoma: a clinicopathological and molecular study of 13 cases.
Pan X; Zhang M; Yao J; Zeng H; Nie L; Gong J; Chen X; Xu M; Zhou Q; Chen N
J Clin Pathol; 2019 Nov; 72(11):748-754. PubMed ID: 31262952
[TBL] [Abstract][Full Text] [Related]
8. Utilization of a TFE3 break-apart FISH assay in a renal tumor consultation service.
Green WM; Yonescu R; Morsberger L; Morris K; Netto GJ; Epstein JI; Illei PB; Allaf M; Ladanyi M; Griffin CA; Argani P
Am J Surg Pathol; 2013 Aug; 37(8):1150-63. PubMed ID: 23715164
[TBL] [Abstract][Full Text] [Related]
9. Expanding the morphologic spectrum of chromophobe renal cell carcinoma: A study of 8 cases with papillary architecture.
Michalova K; Tretiakova M; Pivovarcikova K; Alaghehbandan R; Perez Montiel D; Ulamec M; Osunkoya A; Trpkov K; Yuan G; Grossmann P; Sperga M; Ferak I; Rogala J; Mareckova J; Pitra T; Kolar J; Michal M; Hes O
Ann Diagn Pathol; 2020 Feb; 44():151448. PubMed ID: 31918172
[TBL] [Abstract][Full Text] [Related]
10. Fumarate Hydratase-deficient Renal Cell Carcinoma Is Strongly Correlated With Fumarate Hydratase Mutation and Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome.
Trpkov K; Hes O; Agaimy A; Bonert M; Martinek P; Magi-Galluzzi C; Kristiansen G; Lüders C; Nesi G; Compérat E; Sibony M; Berney DM; Mehra R; Brimo F; Hartmann A; Husain A; Frizzell N; Hills K; Maclean F; Srinivasan B; Gill AJ
Am J Surg Pathol; 2016 Jul; 40(7):865-75. PubMed ID: 26900816
[TBL] [Abstract][Full Text] [Related]
11. Xp11 Translocation Renal Cell Carcinomas (RCCs) With RBM10-TFE3 Gene Fusion Demonstrating Melanotic Features and Overlapping Morphology With t(6;11) RCC: Interest and Diagnostic Pitfall in Detecting a Paracentric Inversion of TFE3.
Xia QY; Wang XT; Zhan XM; Tan X; Chen H; Liu Y; Shi SS; Wang X; Wei X; Ye SB; Li R; Ma HH; Lu ZF; Zhou XJ; Rao Q
Am J Surg Pathol; 2017 May; 41(5):663-676. PubMed ID: 28288037
[TBL] [Abstract][Full Text] [Related]
12. Reappraisal of Morphologic Differences Between Renal Medullary Carcinoma, Collecting Duct Carcinoma, and Fumarate Hydratase-deficient Renal Cell Carcinoma.
Ohe C; Smith SC; Sirohi D; Divatia M; de Peralta-Venturina M; Paner GP; Agaimy A; Amin MB; Argani P; Chen YB; Cheng L; Colecchia M; Compérat E; Werneck da Cunha I; Epstein JI; Gill AJ; Hes O; Hirsch MS; Jochum W; Kunju LP; Maclean F; Magi-Galluzzi C; McKenney JK; Mehra R; Nesi G; Osunkoya AO; Picken MM; Rao P; Reuter VE; de Oliveira Salles PG; Schultz L; Tickoo SK; Tomlins SA; Trpkov K; Amin MB
Am J Surg Pathol; 2018 Mar; 42(3):279-292. PubMed ID: 29309300
[TBL] [Abstract][Full Text] [Related]
13. Molecular-genetic analysis is essential for accurate classification of renal carcinoma resembling Xp11.2 translocation carcinoma.
Hayes M; Peckova K; Martinek P; Hora M; Kalusova K; Straka L; Daum O; Kokoskova B; Rotterova P; Pivovarčikova K; Branzovsky J; Dubova M; Vesela P; Michal M; Hes O
Virchows Arch; 2015 Mar; 466(3):313-22. PubMed ID: 25544614
[TBL] [Abstract][Full Text] [Related]
14. PSF/SFPQ is a very common gene fusion partner in TFE3 rearrangement-associated perivascular epithelioid cell tumors (PEComas) and melanotic Xp11 translocation renal cancers: clinicopathologic, immunohistochemical, and molecular characteristics suggesting classification as a distinct entity.
Rao Q; Shen Q; Xia QY; Wang ZY; Liu B; Shi SS; Shi QL; Yin HL; Wu B; Ye SB; Li L; Chen JY; Pan MH; Li Q; Li R; Wang X; Zhang RS; Yu B; Ma HH; Lu ZF; Zhou XJ
Am J Surg Pathol; 2015 Sep; 39(9):1181-96. PubMed ID: 26274027
[TBL] [Abstract][Full Text] [Related]
15. [Renal cell carcinoma with t(6;11)(p21.2;q13)/MALAT1-TFEB fusion: a clinical and pathological analysis].
Xia Q; Shi S; Shen Q; Wei X; Wang X; Ma H; Lu Z; Zhou X; Rao Q
Zhonghua Bing Li Xue Za Zhi; 2015 Dec; 44(12):895-9. PubMed ID: 26888508
[TBL] [Abstract][Full Text] [Related]
16. SFPQ/PSF-TFE3 renal cell carcinoma: a clinicopathologic study emphasizing extended morphology and reviewing the differences between SFPQ-TFE3 RCC and the corresponding mesenchymal neoplasm despite an identical gene fusion.
Wang XT; Xia QY; Ni H; Ye SB; Li R; Wang X; Shi SS; Zhou XJ; Rao Q
Hum Pathol; 2017 May; 63():190-200. PubMed ID: 28315422
[TBL] [Abstract][Full Text] [Related]
17. Xp11.2 translocation renal cell carcinoma with NONO-TFE3 gene fusion: morphology, prognosis, and potential pitfall in detecting TFE3 gene rearrangement.
Xia QY; Wang Z; Chen N; Gan HL; Teng XD; Shi SS; Wang X; Wei X; Ye SB; Li R; Ma HH; Lu ZF; Zhou XJ; Rao Q
Mod Pathol; 2017 Mar; 30(3):416-426. PubMed ID: 27934879
[TBL] [Abstract][Full Text] [Related]
18. [Oncocytic papillary renal cell carcinoma: a clinicopathological analysis of nineteen cases].
Zhang W; Zhang LX; Yang T; Zou YW; Liu XL; Yu WJ; Jiang YX; Li YJ
Zhonghua Bing Li Xue Za Zhi; 2022 Oct; 51(10):981-986. PubMed ID: 36207910
[No Abstract] [Full Text] [Related]
19. TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum.
Rao Q; Williamson SR; Zhang S; Eble JN; Grignon DJ; Wang M; Zhou XJ; Huang W; Tan PH; Maclennan GT; Cheng L
Am J Surg Pathol; 2013 Jun; 37(6):804-15. PubMed ID: 23598965
[TBL] [Abstract][Full Text] [Related]
20. [Clinicopathological features and differential diagnosis of eosionphilic chromophobe renal cell carcinoma].
Zhang W; Song TT; He B; Wang H; Kang EH; Yu WJ; Zhong DC; Jiang YX; Li YJ
Zhonghua Bing Li Xue Za Zhi; 2020 Dec; 49(12):1242-1248. PubMed ID: 33287507
[No Abstract] [Full Text] [Related]
[Next] [New Search]
